PROPHYLACTIC ANTIBIOTIC TREATMENTIN END-STAGE KIDNEY DISEASE AND CENTRAL VENOUS CATHETER ASHEMODIALYSIS VASCULAR ACCESS

iels Eske Bruun0 个研究点目标入组 800 人开始时间: 2020年4月17日最近更新: 2024年8月5日

适应症

试验速览

暂无简介。

•End Stage Kidney Disease (ESKD) patients who receive an uncuffed or cuffed CVC for expected chronic HD, regardless of previous ESKD treatment modality (PD or KTX) and hemodialysis access (AV-fistula or AV-graft))
•> 18 years
•Ability to understand the study background, risk and benefit of treatment and to give written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 300
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 500

•Unable to give informed consent
•Known intolerance to beta-lactam antibiotics and clindamycin
•Active infection treated with antibiotics.
•Pregnancy. In women of childbearing age, an approved birth control must be ensured.
•Patients may be rescreened later i.e. within a time period of one month from start of HD, if exclusion criteria are reversible

发起方

iels Eske Bruun